Perspective Therapeutics, Inc. (AMEX: CATX) Stock Competitors & Peer Comparison

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CATX's ROE is -0.42%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, CATX is more volatile compared to BSX-PA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BSX-PA's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ABT has a market cap of 175.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ABT trades at $101.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ABT's P/E ratio is 19.44. In terms of profitability, CATX's ROE is -0.42%, compared to ABT's ROE of +0.11%. Regarding short-term risk, CATX is more volatile compared to ABT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ABT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, MDT has a market cap of 113.5B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while MDT trades at $88.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas MDT's P/E ratio is 16.03. In terms of profitability, CATX's ROE is -0.42%, compared to MDT's ROE of +0.11%. Regarding short-term risk, CATX is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check MDT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SYK has a market cap of 104.5B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SYK trades at $272.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SYK's P/E ratio is 20.35. In terms of profitability, CATX's ROE is -0.42%, compared to SYK's ROE of +0.16%. Regarding short-term risk, CATX is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SYK's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BSX has a market cap of 65.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BSX trades at $43.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BSX's P/E ratio is 14.17. In terms of profitability, CATX's ROE is -0.42%, compared to BSX's ROE of +0.15%. Regarding short-term risk, CATX is less volatile compared to BSX. This indicates lower risk in terms of short-term price fluctuations for CATX.Check BSX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, EW has a market cap of 49.7B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while EW trades at $86.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas EW's P/E ratio is 31.96. In terms of profitability, CATX's ROE is -0.42%, compared to EW's ROE of +0.10%. Regarding short-term risk, CATX is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for CATX.Check EW's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, DXCM has a market cap of 32.7B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while DXCM trades at $86.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas DXCM's P/E ratio is 33.97. In terms of profitability, CATX's ROE is -0.42%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, CATX is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for CATX.Check DXCM's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, GEHC has a market cap of 30.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while GEHC trades at $66.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas GEHC's P/E ratio is 14.61. In terms of profitability, CATX's ROE is -0.42%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, CATX is more volatile compared to GEHC. This indicates higher risk in terms of short-term price fluctuations for CATX.Check GEHC's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, PHG has a market cap of 24.4B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while PHG trades at $24.96.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas PHG's P/E ratio is 14.26. In terms of profitability, CATX's ROE is -0.42%, compared to PHG's ROE of +0.10%. Regarding short-term risk, CATX is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PHG's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ZBH has a market cap of 17.6B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ZBH trades at $91.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ZBH's P/E ratio is 10.73. In terms of profitability, CATX's ROE is -0.42%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, CATX is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ZBH's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CATX's ROE is -0.42%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CATX is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ABMD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CATX's ROE is -0.42%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, CATX is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SWAV's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while PEN trades at $318.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas PEN's P/E ratio is 83.25. In terms of profitability, CATX's ROE is -0.42%, compared to PEN's ROE of +0.11%. Regarding short-term risk, CATX is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PEN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SNN has a market cap of 11.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SNN trades at $26.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SNN's P/E ratio is 18.17. In terms of profitability, CATX's ROE is -0.42%, compared to SNN's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SNN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BIO-B has a market cap of 10.5B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BIO-B trades at $385.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BIO-B's P/E ratio is -67.89. In terms of profitability, CATX's ROE is -0.42%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, CATX is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BIO-B's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ALGN has a market cap of 10.5B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ALGN trades at $146.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ALGN's P/E ratio is 13.38. In terms of profitability, CATX's ROE is -0.42%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, CATX is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ALGN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BIO has a market cap of 10.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BIO trades at $381.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BIO's P/E ratio is 41.05. In terms of profitability, CATX's ROE is -0.42%, compared to BIO's ROE of +0.03%. Regarding short-term risk, CATX is more volatile compared to BIO. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BIO's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, GMED has a market cap of 10.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while GMED trades at $74.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas GMED's P/E ratio is 16.79. In terms of profitability, CATX's ROE is -0.42%, compared to GMED's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for CATX.Check GMED's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BRKR has a market cap of 9.8B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BRKR trades at $64.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BRKR's P/E ratio is 32.25. In terms of profitability, CATX's ROE is -0.42%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, CATX is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for CATX.Check BRKR's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BRKRP has a market cap of 9.4B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BRKRP trades at $470.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BRKRP's P/E ratio is 255.66. In terms of profitability, CATX's ROE is -0.42%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, CATX is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for CATX.Check BRKRP's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, PODD has a market cap of 9.4B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while PODD trades at $136.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas PODD's P/E ratio is 23.19. In terms of profitability, CATX's ROE is -0.42%, compared to PODD's ROE of +0.27%. Regarding short-term risk, CATX is more volatile compared to PODD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check PODD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while MASI trades at $179.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas MASI's P/E ratio is 44.43. In terms of profitability, CATX's ROE is -0.42%, compared to MASI's ROE of +0.09%. Regarding short-term risk, CATX is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for CATX.Check MASI's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, GKOS has a market cap of 9.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while GKOS trades at $154.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas GKOS's P/E ratio is -180.02. In terms of profitability, CATX's ROE is -0.42%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, CATX is more volatile compared to GKOS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check GKOS's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, HAE has a market cap of 4.8B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while HAE trades at $105.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas HAE's P/E ratio is 21.02. In terms of profitability, CATX's ROE is -0.42%, compared to HAE's ROE of +0.11%. Regarding short-term risk, CATX is more volatile compared to HAE. This indicates higher risk in terms of short-term price fluctuations for CATX.Check HAE's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas NARI's P/E ratio is -59.24. In terms of profitability, CATX's ROE is -0.42%, compared to NARI's ROE of -0.00%. Regarding short-term risk, CATX is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NARI's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ITGR trades at $126.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ITGR's P/E ratio is 19.89. In terms of profitability, CATX's ROE is -0.42%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, CATX is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ITGR's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, LIVN has a market cap of 4.2B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while LIVN trades at $76.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas LIVN's P/E ratio is 18.20. In terms of profitability, CATX's ROE is -0.42%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, CATX is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check LIVN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas AXNX's P/E ratio is -709.80. In terms of profitability, CATX's ROE is -0.42%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, CATX is more volatile compared to AXNX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check AXNX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, IRTC has a market cap of 3.6B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while IRTC trades at $110.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas IRTC's P/E ratio is -256.70. In terms of profitability, CATX's ROE is -0.42%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, CATX is more volatile compared to IRTC. This indicates higher risk in terms of short-term price fluctuations for CATX.Check IRTC's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, NEOG has a market cap of 3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while NEOG trades at $13.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas NEOG's P/E ratio is 49.14. In terms of profitability, CATX's ROE is -0.42%, compared to NEOG's ROE of -0.00%. Regarding short-term risk, CATX is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for CATX.Check NEOG's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, TMDX has a market cap of 2.9B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while TMDX trades at $85.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas TMDX's P/E ratio is 43.29. In terms of profitability, CATX's ROE is -0.42%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, CATX is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for CATX.Check TMDX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BFLY has a market cap of 2.5B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BFLY trades at $9.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BFLY's P/E ratio is -39.13. In terms of profitability, CATX's ROE is -0.42%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, CATX is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for CATX.Check BFLY's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, AXGN has a market cap of 2.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while AXGN trades at $43.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas AXGN's P/E ratio is 114.18. In terms of profitability, CATX's ROE is -0.42%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, CATX is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for CATX.Check AXGN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while UFPT trades at $295.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas UFPT's P/E ratio is 30.20. In terms of profitability, CATX's ROE is -0.42%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, CATX is more volatile compared to UFPT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check UFPT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CATX's ROE is -0.42%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CATX is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for CATX.Check NUVA's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, INSP has a market cap of 2B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while INSP trades at $70.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas INSP's P/E ratio is 31.06. In terms of profitability, CATX's ROE is -0.42%, compared to INSP's ROE of +0.18%. Regarding short-term risk, CATX is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for CATX.Check INSP's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ESTA trades at $65.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ESTA's P/E ratio is -52.36. In terms of profitability, CATX's ROE is -0.42%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, CATX is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for CATX.Check ESTA's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, NVCR has a market cap of 1.8B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while NVCR trades at $15.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas NVCR's P/E ratio is -12.18. In terms of profitability, CATX's ROE is -0.42%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, CATX is more volatile compared to NVCR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NVCR's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ATEC has a market cap of 1.6B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ATEC trades at $10.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ATEC's P/E ratio is -168.67. In terms of profitability, CATX's ROE is -0.42%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, CATX is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for CATX.Check ATEC's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while CNMD trades at $45.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas CNMD's P/E ratio is 9.97. In terms of profitability, CATX's ROE is -0.42%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, CATX is more volatile compared to CNMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CNMD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CATX's ROE is -0.42%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CATX is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check HSKA's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, IART has a market cap of 1.3B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while IART trades at $16.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas IART's P/E ratio is 6.83. In terms of profitability, CATX's ROE is -0.42%, compared to IART's ROE of -0.01%. Regarding short-term risk, CATX is more volatile compared to IART. This indicates higher risk in terms of short-term price fluctuations for CATX.Check IART's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while AVNS trades at $24.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas AVNS's P/E ratio is 27.77. In terms of profitability, CATX's ROE is -0.42%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, CATX is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check AVNS's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SILK's P/E ratio is -18.96. In terms of profitability, CATX's ROE is -0.42%, compared to SILK's ROE of -0.35%. Regarding short-term risk, CATX is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SILK's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while AORT trades at $22.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas AORT's P/E ratio is 37.75. In terms of profitability, CATX's ROE is -0.42%, compared to AORT's ROE of -0.01%. Regarding short-term risk, CATX is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for CATX.Check AORT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas FNA's P/E ratio is -19.83. In terms of profitability, CATX's ROE is -0.42%, compared to FNA's ROE of -0.35%. Regarding short-term risk, CATX is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for CATX.Check FNA's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while IRMD trades at $85.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas IRMD's P/E ratio is 43.10. In terms of profitability, CATX's ROE is -0.42%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, CATX is more volatile compared to IRMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check IRMD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, TNDM has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while TNDM trades at $15.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas TNDM's P/E ratio is -16.90. In terms of profitability, CATX's ROE is -0.42%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, CATX is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for CATX.Check TNDM's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ENOV has a market cap of 1.1B. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ENOV trades at $18.46.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ENOV's P/E ratio is 5.29. In terms of profitability, CATX's ROE is -0.42%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, CATX is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for CATX.Check ENOV's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, LMRI has a market cap of 981M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while LMRI trades at $10.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas LMRI's P/E ratio is -19.86. In terms of profitability, CATX's ROE is -0.42%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, CATX is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check LMRI's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, PRCT has a market cap of 979M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while PRCT trades at $17.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas PRCT's P/E ratio is -8.87. In terms of profitability, CATX's ROE is -0.42%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, CATX is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for CATX.Check PRCT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BBNX has a market cap of 967.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BBNX trades at $21.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BBNX's P/E ratio is -13.04. In terms of profitability, CATX's ROE is -0.42%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, CATX is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for CATX.Check BBNX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BVS has a market cap of 935.6M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BVS trades at $13.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BVS's P/E ratio is 18.17. In terms of profitability, CATX's ROE is -0.42%, compared to BVS's ROE of +0.28%. Regarding short-term risk, CATX is less volatile compared to BVS. This indicates lower risk in terms of short-term price fluctuations for CATX.Check BVS's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, CBLL has a market cap of 898.9M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while CBLL trades at $23.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas CBLL's P/E ratio is -13.46. In terms of profitability, CATX's ROE is -0.42%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, CATX is more volatile compared to CBLL. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CBLL's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas CSII's P/E ratio is -20.83. In terms of profitability, CATX's ROE is -0.42%, compared to CSII's ROE of -0.14%. Regarding short-term risk, CATX is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CSII's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SIBN has a market cap of 824.5M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SIBN trades at $18.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SIBN's P/E ratio is -54.68. In terms of profitability, CATX's ROE is -0.42%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, CATX is more volatile compared to SIBN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SIBN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, INMD has a market cap of 819.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while INMD trades at $14.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas INMD's P/E ratio is 9.90. In terms of profitability, CATX's ROE is -0.42%, compared to INMD's ROE of +0.12%. Regarding short-term risk, CATX is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check INMD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, VREX has a market cap of 776.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while VREX trades at $18.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas VREX's P/E ratio is 19.42. In terms of profitability, CATX's ROE is -0.42%, compared to VREX's ROE of +0.05%. Regarding short-term risk, CATX is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check VREX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, AHCO has a market cap of 767.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while AHCO trades at $5.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas AHCO's P/E ratio is 11.51. In terms of profitability, CATX's ROE is -0.42%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, CATX is more volatile compared to AHCO. This indicates higher risk in terms of short-term price fluctuations for CATX.Check AHCO's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, AVR has a market cap of 747.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while AVR trades at $7.69.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas AVR's P/E ratio is -3.96. In terms of profitability, CATX's ROE is -0.42%, compared to AVR's ROE of -0.78%. Regarding short-term risk, CATX is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for CATX.Check AVR's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, CTKB has a market cap of 729.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while CTKB trades at $5.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas CTKB's P/E ratio is -29.93. In terms of profitability, CATX's ROE is -0.42%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, CATX is more volatile compared to CTKB. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CTKB's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SRDX's P/E ratio is -34.66. In terms of profitability, CATX's ROE is -0.42%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, CATX is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SRDX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SSII has a market cap of 590.4M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SSII trades at $2.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SSII's P/E ratio is -49.17. In terms of profitability, CATX's ROE is -0.42%, compared to SSII's ROE of -0.27%. Regarding short-term risk, CATX is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for CATX.Check SSII's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas APEN's P/E ratio is -9.43. In terms of profitability, CATX's ROE is -0.42%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CATX is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for CATX.Check APEN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, KIDS has a market cap of 579.2M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while KIDS trades at $22.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas KIDS's P/E ratio is -19.11. In terms of profitability, CATX's ROE is -0.42%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, CATX is more volatile compared to KIDS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check KIDS's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, DCTH has a market cap of 538.5M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while DCTH trades at $15.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas DCTH's P/E ratio is 1560.00. In terms of profitability, CATX's ROE is -0.42%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, CATX is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for CATX.Check DCTH's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, CATX's ROE is -0.42%, compared to ZIMV's ROE of -0.01%. Regarding short-term risk, CATX is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ZIMV's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, CERS has a market cap of 528M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while CERS trades at $2.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas CERS's P/E ratio is -87.04. In terms of profitability, CATX's ROE is -0.42%, compared to CERS's ROE of -0.10%. Regarding short-term risk, CATX is more volatile compared to CERS. This indicates higher risk in terms of short-term price fluctuations for CATX.Check CERS's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, TCMD has a market cap of 512.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while TCMD trades at $22.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas TCMD's P/E ratio is 21.05. In terms of profitability, CATX's ROE is -0.42%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, CATX is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check TCMD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, PACB has a market cap of 503.2M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while PACB trades at $1.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas PACB's P/E ratio is -3.95. In terms of profitability, CATX's ROE is -0.42%, compared to PACB's ROE of -49.62%. Regarding short-term risk, CATX is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for CATX.Check PACB's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SGHT has a market cap of 485.9M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SGHT trades at $8.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SGHT's P/E ratio is -15.95. In terms of profitability, CATX's ROE is -0.42%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, CATX is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for CATX.Check SGHT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, NPCE has a market cap of 479.4M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while NPCE trades at $14.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas NPCE's P/E ratio is -24.67. In terms of profitability, CATX's ROE is -0.42%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, CATX is more volatile compared to NPCE. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NPCE's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, CLPT has a market cap of 444.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while CLPT trades at $14.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas CLPT's P/E ratio is -12.57. In terms of profitability, CATX's ROE is -0.42%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, CATX is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for CATX.Check CLPT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SENS has a market cap of 417.9M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SENS trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SENS's P/E ratio is -4.48. In terms of profitability, CATX's ROE is -0.42%, compared to SENS's ROE of -1.66%. Regarding short-term risk, CATX is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for CATX.Check SENS's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, OFIX has a market cap of 381.6M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while OFIX trades at $9.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas OFIX's P/E ratio is -6.15. In terms of profitability, CATX's ROE is -0.42%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, CATX is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for CATX.Check OFIX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, CV has a market cap of 332.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while CV trades at $6.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas CV's P/E ratio is -10.56. In terms of profitability, CATX's ROE is -0.42%, compared to CV's ROE of -1.78%. Regarding short-term risk, CATX is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for CATX.Check CV's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas SMLR's P/E ratio is 3.92. In terms of profitability, CATX's ROE is -0.42%, compared to SMLR's ROE of +0.06%. Regarding short-term risk, CATX is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for CATX.Check SMLR's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, RCEL has a market cap of 294.1M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while RCEL trades at $11.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas RCEL's P/E ratio is -8.22. In terms of profitability, CATX's ROE is -0.42%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, CATX is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for CATX.Check RCEL's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, TMCI has a market cap of 291.9M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while TMCI trades at $4.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas TMCI's P/E ratio is -4.79. In terms of profitability, CATX's ROE is -0.42%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, CATX is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check TMCI's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, TLSI has a market cap of 267.2M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while TLSI trades at $4.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas TLSI's P/E ratio is -2.58. In terms of profitability, CATX's ROE is -0.42%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, CATX is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check TLSI's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, INFU has a market cap of 257.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while INFU trades at $12.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas INFU's P/E ratio is 31.10. In terms of profitability, CATX's ROE is -0.42%, compared to INFU's ROE of +0.15%. Regarding short-term risk, CATX is more volatile compared to INFU. This indicates higher risk in terms of short-term price fluctuations for CATX.Check INFU's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas MGRM's P/E ratio is -12.00. In terms of profitability, CATX's ROE is -0.42%, compared to MGRM's ROE of -0.85%. Regarding short-term risk, CATX is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for CATX.Check MGRM's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ELMD has a market cap of 231.4M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ELMD trades at $27.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ELMD's P/E ratio is 21.34. In terms of profitability, CATX's ROE is -0.42%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, CATX is more volatile compared to ELMD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ELMD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CATX's ROE is -0.42%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, CATX is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for CATX.Check NVRO's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, PROF has a market cap of 209.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while PROF trades at $5.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas PROF's P/E ratio is -5.88. In terms of profitability, CATX's ROE is -0.42%, compared to PROF's ROE of -0.56%. Regarding short-term risk, CATX is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for CATX.Check PROF's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, RXST has a market cap of 192.9M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while RXST trades at $4.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas RXST's P/E ratio is -4.12. In terms of profitability, CATX's ROE is -0.42%, compared to RXST's ROE of -0.17%. Regarding short-term risk, CATX is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for CATX.Check RXST's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas BSGM's P/E ratio is -5.81. In terms of profitability, CATX's ROE is -0.42%, compared to BSGM's ROE of +15.26%. Regarding short-term risk, CATX is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for CATX.Check BSGM's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, STIM has a market cap of 190.7M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while STIM trades at $2.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas STIM's P/E ratio is -6.23. In terms of profitability, CATX's ROE is -0.42%, compared to STIM's ROE of -1.51%. Regarding short-term risk, CATX is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for CATX.Check STIM's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas MDGS's P/E ratio is -0.27. In terms of profitability, CATX's ROE is -0.42%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, CATX is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for CATX.Check MDGS's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, FOCL has a market cap of 176.5M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while FOCL trades at $4.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas FOCL's P/E ratio is -4.55. In terms of profitability, CATX's ROE is -0.42%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, CATX is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for CATX.Check FOCL's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, QSI has a market cap of 165M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while QSI trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas QSI's P/E ratio is -1.81. In terms of profitability, CATX's ROE is -0.42%, compared to QSI's ROE of -0.47%. Regarding short-term risk, CATX is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check QSI's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while QIPT trades at $3.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas QIPT's P/E ratio is -15.87. In terms of profitability, CATX's ROE is -0.42%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, CATX is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for CATX.Check QIPT's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, LUCD has a market cap of 157.6M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while LUCD trades at $0.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas LUCD's P/E ratio is -2.23. In terms of profitability, CATX's ROE is -0.42%, compared to LUCD's ROE of -4.04%. Regarding short-term risk, CATX is less volatile compared to LUCD. This indicates lower risk in terms of short-term price fluctuations for CATX.Check LUCD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, QTRX has a market cap of 154M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while QTRX trades at $3.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas QTRX's P/E ratio is -1.29. In terms of profitability, CATX's ROE is -0.42%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, CATX is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for CATX.Check QTRX's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, INGN has a market cap of 145.1M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while INGN trades at $5.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas INGN's P/E ratio is -5.89. In terms of profitability, CATX's ROE is -0.42%, compared to INGN's ROE of -0.13%. Regarding short-term risk, CATX is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for CATX.Check INGN's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ICAD trades at $3.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ICAD's P/E ratio is -20.37. In terms of profitability, CATX's ROE is -0.42%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, CATX is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ICAD's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ECOR has a market cap of 100.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ECOR trades at $11.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ECOR's P/E ratio is -6.62. In terms of profitability, CATX's ROE is -0.42%, compared to ECOR's ROE of +5.25%. Regarding short-term risk, CATX is less volatile compared to ECOR. This indicates lower risk in terms of short-term price fluctuations for CATX.Check ECOR's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while HJLI trades at $10.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas HJLI's P/E ratio is N/A. In terms of profitability, CATX's ROE is -0.42%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, CATX is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for CATX.Check HJLI's competition here

Perspective Therapeutics, Inc. (AMEX: CATX) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CATX stands at 286.3M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, CATX is priced at $2.52 on the AMEX, while ASXC trades at $0.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CATX currently has a P/E ratio of -1.89, whereas ASXC's P/E ratio is -1.12. In terms of profitability, CATX's ROE is -0.42%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, CATX is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for CATX.Check ASXC's competition here